Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6152560 | 0.87 | HTR7 (0.50) | HTR7CYP3A4TSHRALDH1A1MAPT | |
| SCHEMBL11508113 | 0.86 | CYP3A4 (0.56) | HTR7CYP3A4TSHRALDH1A1MAPT | |
| SCHEMBL9149358 | 0.85 | HTR7 (0.49) | HTR7CYP3A4TSHRALDH1A1MAPT | |
| Bromide SCHEMBL21436754 | 0.85 | HTR7 (0.49) | HTR7CYP3A4TSHRALDH1A1MAPT | |
| SCHEMBL5159176 | 0.85 | HTR7 (0.51) | HTR7CYP3A4TSHRALDH1A1MAPT | |
| SCHEMBL11934987 | 0.84 | HTR7 (0.48) | HTR7CYP3A4TSHRALDH1A1MAPT | |
| SCHEMBL3224710 | 0.83 | F2R (0.50) | HTR7CYP3A4TSHRALDH1A1MAPT | |
| SCHEMBL6151959 | 0.82 | KMT2A (0.48) | HTR7CYP3A4TSHRALDH1A1MAPT | |
| SCHEMBL1220305 | 0.81 | HTR7 (0.49) | HTR7CYP3A4TSHRALDH1A1MAPT | |
| SCHEMBL6408527 | 0.81 | HTR7 (0.49) | HTR7CYP3A4TSHRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569337-B2 | Labeling brain tissues in vivo or in vitro; 3-Benzothiazol-2-yl-7-[4-(2-fluoro-ethyl)-piperazin-1-yl]-chromen-2-one; diagnosis, monitoring the effectiveness of a therapeutic treatment and detecting histopathological hallmarks of Alzheimer's disease | NOVARTIS AG (CH) | 2009-08-04 | — | — | US | disclosed |
| US-20050169837-A1 | Coumarines useful as biomarkers | NOVARTIS AG (CH) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050169837-A1 | Coumarines useful as biomarkers | CCNB1, CBR1, CYP1A1 | HTR7 3352/4885CYP3A4 20/4885TSHR 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.